ArticleFrontiers in pharmacology2021
The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Guideline
- Blood-Brain Barrier Changes and Related Microvascular Outcomes in Long-COVID: A Comprehensive Review.Life (Basel, Switzerland) · 2026Review
- Validation in Drosophila of the in silico predicted clomipramine as repurposable for SOD1-ALS.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Bridging Gaps in Long COVID Therapy: A Review.Current medicinal chemistry · 2026Review
- Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19.Infection & chemotherapy · 2025Review
- Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment.Cells · 2025Review
- Reactivity of Olanzapine and Tricyclic Antidepressants on the Protective Effects of Trolox on Lipid Peroxidation Evaluated Using Fluorescence Anisotropy, Electron Paramagnetic Resonance Spectrometry, and Thermal Analysis.ACS chemical neuroscience · 2025Article
- The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.Infection & chemotherapy · 2024Review
- Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series.Frontiers in psychiatry · 2024Article
- Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19.Cellular and molecular neurobiology · 2023Review
- Sub-cellular sequestration of alkaline drugs in lysosomes: new insights for pharmaceutical development of lysosomal fluid.Research in pharmaceutical sciences · 2023Article
- Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma.Current neuropharmacology · 2022Observational
- Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use.European journal of clinical pharmacology · 2022Review
- Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.Infection & chemotherapy · 2022Review
- Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies.Scientific reports · 2022Article
- Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder.Journal of psychiatric research · 2022Review
- Mental Health Issues During and After COVID-19 Vaccine Era.Brain research bulletin · 2021Review
- Sphingolipids as Modulators of SARS-CoV-2 Infection.Frontiers in cell and developmental biology · 2021Review
- Response to Letter to the Editor from Finsterer: "Encephalitis Associated With SARS-CoV-2 Infection in a Child With Chiari Malformation Type I".In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At the time of writing (December 2020), coronavirus disease 2019 (COVID-19) has already caused more than one million deaths worldwide, and therefore, it is imperative to find effective treatments. The "cytokine storm" induced by Severe Acute Respiratory Syndrome-Coronavirus type 2 (SARS-CoV-2) is a good target to prevent disease worsening, as indicated by the results obtained with tocilizumab and dexamethasone. SARS-CoV-2 can also invade the brain and cause neuro-inflammation with dramatic neurological manifestations, such as viral encephalitis. This could lead to potentially incapacitating long-term consequences, such as the development of psychiatric disorders, as previously observed with SARS-CoV. Several pathways/mechanisms could explain the link between viral infection and development of psychiatric diseases, especially neuro-inflammation induced by SARS-CoV-2. Therefore, it is important to find molecules with anti-inflammatory properties that penetrate easily into the brain. For instance, some antidepressants have anti-inflammatory action and pass easily through the blood brain barrier. Among them, clomipramine has shown very strong anti-inflammatory properties
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.